Karen M. Anderson Sells 51,160 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Karen M. Anderson sold 51,160 shares of the firm’s stock in a transaction that occurred on Monday, March 25th. The shares were sold at an average price of $11.88, for a total transaction of $607,780.80. Following the completion of the transaction, the insider now directly owns 71,525 shares of the company’s stock, valued at approximately $849,717. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Centessa Pharmaceuticals Trading Up 3.2 %

NASDAQ CNTA opened at $11.10 on Thursday. The firm has a 50 day simple moving average of $9.95 and a 200-day simple moving average of $7.88. The company has a debt-to-equity ratio of 0.29, a quick ratio of 9.51 and a current ratio of 9.51. Centessa Pharmaceuticals plc has a one year low of $3.52 and a one year high of $12.45. The firm has a market cap of $1.08 billion, a price-to-earnings ratio of -6.77 and a beta of 1.37.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CNTA. Platinum Investment Management Ltd. raised its holdings in Centessa Pharmaceuticals by 96.7% in the third quarter. Platinum Investment Management Ltd. now owns 337,544 shares of the company’s stock valued at $2,184,000 after acquiring an additional 165,919 shares in the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in Centessa Pharmaceuticals by 25.8% in the third quarter. Adage Capital Partners GP L.L.C. now owns 2,830,500 shares of the company’s stock valued at $18,313,000 after acquiring an additional 580,500 shares in the last quarter. Acuta Capital Partners LLC acquired a new stake in Centessa Pharmaceuticals in the third quarter valued at approximately $2,092,000. Affinity Asset Advisors LLC raised its holdings in Centessa Pharmaceuticals by 13.0% in the third quarter. Affinity Asset Advisors LLC now owns 1,018,091 shares of the company’s stock valued at $6,587,000 after acquiring an additional 117,368 shares in the last quarter. Finally, Rathbones Group PLC acquired a new position in shares of Centessa Pharmaceuticals in the 3rd quarter valued at $203,000. Hedge funds and other institutional investors own 82.01% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its pipeline products include SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of NT1 with potential expansion into other sleep disorders.